Enclomiphene vs Sermorelin: What the Research Shows
Enclomiphene and Sermorelin side by side: what they are, how they are regulated and what is still unknown.
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Quick verdict
Summary of studies, not a recommendationWhere the research points
Consider Enclomiphene if…
- you want an oral option with randomized testosterone data against a gel: At 25 mg daily, day-42 testosterone averaged 604 ng/dL versus 500 ng for transdermal testosterone.[4]
- you want randomized data on sperm concentration versus testosterone gel: Sperm concentration stayed in the normal range with enclomiphene but fell markedly with testosterone gel.[3]
Consider Sermorelin if…
- you want human data in growth-hormone-deficient children, though uncontrolled: Mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months (open-label, no control group).[20]
What they have in common
- Sermorelin's only FDA record is Geref, listed with marketing status Discontinued[21]
Sermorelin is not FDA approved. Both are prohibited in tested sport (WADA). Status labels come from public FDA and WADA records; see the sources below.
Side by side
Spec comparison
Showing 9 of 12 fields where the two differ. PCAC vote, Jul 2026, Half-life, Evidence strength are the same or both unknown.
| Field | Enclomiphene | Sermorelin |
|---|---|---|
| Class | SERM (not a peptide) | GHRH analog |
| Also called | enclo | — |
| Category | Other | Growth hormone |
| FDA status | Not FDA approved · compounded | Compounded by prescription |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S4.2)Enclomiphene is an isomer of clomifene, which is named in S4.2 (anti-estrogens/SERMs, prohibited at all times). Enclomiphene itself is not spelled out in the list text we cached, so this rests on it being a form of clomifene. | Prohibited by WADA (S2.2.4)Sermorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. |
| Anti-doping detection |
|
|
| Half-life | No published half-life foundPubMed search, 2 Oct 2026 | No published half-life foundPubMed search, 2 Oct 2026 |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: BJU international 2016, PMID 26496621 | Human RCT evidence, 4 of 4Strongest: The Journal of clinical endocrinology and metabolism 1992, PMID 1379256 |
| Human studies we summarised | 6 human (4 randomized or controlled) of 9 summarised | 4 human (1 randomized or controlled) of 7 summarised |
| Typical study doses |
|
|
| US searches per month | 135,000 · +40% searches | 165,000 · Flat YoY |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
Taken together?
Enclomiphene and Sermorelin together
People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 0 results, 2 Oct 2026).
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2Hypothalamic-Pituitary-Testicular Axis Effects and Urinary Detection Following Clomiphene Administration in Males.The Journal of clinical endocrinology and metabolism · 2019PMID 30295816Accessed 2 Oct 2026
- 3Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement.BJU international · 2016PMID 26496621Accessed 2 Oct 2026
- 4Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics.BJU international · 2013PMID 23875626Accessed 2 Oct 2026
- 5Newly Detected Atrial Flutter After Enclomiphene Dose Escalation in a Patient With Prior Mitral Valve Repair and Chronic Immune Thrombocytopenia: A Case Report.Cureus · 2026PMID 42741668Accessed 2 Oct 2026
- 6PubMed search: enclomiphene[tiab] OR enclomifene[tiab] OR "trans-clomiphene"[tiab] (98 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search: (enclomiphene[tiab] OR enclomifene[tiab]) AND (randomized controlled trial[pt] OR clinical trial[pt] OR meta-analysis[pt]) (9 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: (enclomiphene[tiab] OR enclomifene[tiab]) AND (hypogonadism[tiab] OR testosterone[tiab]) AND humans[mh] (17 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: (enclomiphene[tiab] OR enclomifene[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
- 11Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
- 12Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
- 13Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
- 14Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
- 15PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 17PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 18PubMed search: (enclomiphene[tiab] OR enclomifene[tiab] OR "trans-clomiphene"[tiab] OR Androxal[tiab]) AND (sermorelin[tiab] OR Geref[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 19Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone.Fertility and sterility · 2014PMID 25044085Accessed 2 Oct 2026
- 20Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
- 21Drugs@FDA (openFDA) search: active ingredient "sermorelin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.